SAN CARLOS, Calif.--(BUSINESS WIRE)-- AcureX Therapeutics Corporation, a privately-held preclinical-stage biotechnology company focused on developing disease altering therapeutics for neurodegenerative diseases, today announced that it was selected to present at the Oppenheimer Biotechnology – Emerging Science Summit on October 15^th, 2021.

Presentation details:

Halting Neurodegeneration with Miro1 Directed Therapies
Presented by: William Shrader, Ph.D., Co-founder and CEO AcureX Therapeutics
Date and time: October 15^th, 2021 at 1:30p.m. ET / 10:30a.m. PT

The Oppenheimer Biotechnology – Emerging Science Summit will be held virtually and will feature Stanford University’s SPARK program. Presentations will be given by experts in the fields of oncology, immunology, neurology, and gene therapy, as well as management from several publicly traded companies.

William Shrader, Ph.D. said, “We at AcureX are pleased to be recognized as a leader in an emerging field and we are delighted to share our novel drug discovery approach at this prestigious forum.”

About AcureX Therapeutics

The mission of AcureX Therapeutics is to halt neurodegenerative diseases driven by impaired mitophagy, starting with Parkinson’s Disease. AcureX expects to have one or more late-preclinical therapeutic candidates for Parkinson’s in human trials within two years, followed by candidates for other neurodegenerative diseases. AcureX’s novel approach and founding intellectual property are based on recent discoveries made by the company’s inventor and co-founder, Xinnan Wang MD, Ph.D. AcureX has built a unique target and drug discovery platform to accelerate drug development and de-risk clinical trials with an exclusive license to the founding intellectual property. The AcureX team is led by veteran scientists with a proven track record in CNS drug development and serial life sciences entrepreneurs. For more information, please visit https://www.acurex.com.

Oppenheimer Biotechnology – Emerging Science Summit Registration

To express interest, please contact your Oppenheimer Institutional Salesperson or email Deena Sullivan at Deena.Sullivan@opco.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20211011005102/en/